Fulranumab
Fulranumab is a human monoclonal antibody designed for the treatment of pain.[1]
Fulranumab was developed by Johnson & Johnson.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems |
|---|
| | Bone ("-os-", "-s(o)-") | Human ("-osu-") | |
|---|
| Humanized ("-sozu-") | |
|---|
|
|---|
| | Musculoskeletal ("-mul-") | |
|---|
| | Circulatory ("-c(i[r])-") | Human ("-ciru-") | |
|---|
| Mouse ("-ciro-") | |
|---|
| Chimeric ("-cixi-") | |
|---|
| | |
|---|
|
|---|
| | Neurologic ("-ne(u)(r)-") | Human ("-neru-") | |
|---|
| Humanized ("-nezu-"/"-neuzu-") | |
|---|
|
|---|
| | Angiogenesis inhibitor ("-anibi-") | |
|---|
| |
|
